Technische Hochschule Ingolstadt, THI Business School, Esplanade 10, D-85049 Ingolstadt, Germany; University of St. Gallen, Institute of Technology Management, Dufourstrasse 40a, CH-9000 St. Gallen, Switzerland.
University of St. Gallen, Institute of Technology Management, Dufourstrasse 40a, CH-9000 St. Gallen, Switzerland.
Drug Discov Today. 2024 Sep;29(9):104128. doi: 10.1016/j.drudis.2024.104128. Epub 2024 Aug 5.
This article addresses the research and development (R&D) productivity challenge of the pharmaceutical industry, focusing on United States Food and Drug Administration (FDA)-related new drug approvals of the top 20 pharmaceutical companies (2014-2023). We evaluated the degree of innovation in new drugs to determine the innovativeness of these leading companies. A key finding of our analysis is the decline in the number of new drugs approved by the FDA for these leading companies over the investigated time period. This trend suggests that some of the leading companies are losing ground in R&D innovation, raising concerns about their ability to sustain competitive advantage, ensure long-term market success, and maintain viable business models.
本文针对制药行业的研发（R&D）生产力挑战进行研究，重点关注美国食品和药物管理局（FDA）批准的前 20 家制药公司（2014-2023 年）的相关新药审批情况。我们评估了新药的创新程度，以确定这些领先公司的创新性。我们分析的一个关键发现是，在调查期间，这些领先公司获得 FDA 批准的新药数量有所减少。这一趋势表明，一些领先公司在研发创新方面正在失去优势，这令人担忧他们是否有能力保持竞争优势、确保长期的市场成功并维持可行的商业模式。
